Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25844191 | 0.84 | LMNA (0.57) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL16994768 | 0.83 | MEN1 (0.63) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL7838255 | 0.83 | HTT (0.61) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL14924441 | 0.83 | AKR1C3 (0.65) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL25839451 | 0.83 | MAPT (0.53) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL22542013 | 0.82 | HTT (0.59) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL12916359 | 0.82 | HTT (0.59) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL24681638 | 0.79 | MAPT (0.68) | MAPTALDH1A1HTTGFERAKR1C3 | |
| SCHEMBL12047642 | 0.79 | MAPT (0.61) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL22542017 | 0.79 | HTT (0.57) | MAPTLMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | MAPT 3409/4885LMNA 4833/4885MEN1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.